MRI-Guided Radiation Therapy in Treating Patients With Prostate Cancer
| Status: | Archived |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Imaging
procedures, such as MRI, may help the doctor send x-rays directly to the tumor and nearby
lymph nodes and cause less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of MRI-guided
radiation therapy in treating patients with prostate cancer.
OBJECTIVES:
- Determine the feasibility of treating the pelvic lymph nodes in patients with prostate
cancer treated with intensity-modulated radiotherapy (IMRT).
- Determine the maximum tolerated dose of IMRT in these patients.
- Determine long term effects and toxicity in patients treated with IMRT.
OUTLINE: This is a pilot, dose-escalation study.
After pathology is available and 2 months of neoadjuvant hormone therapy is complete,
patients undergo MRI-guided intensity-modulated radiotherapy (IMRT) to the at-risk or
positive lymph nodes 5 days a week for 8.5 weeks.
Cohorts of 3-6 patients receive escalating doses of IMRT until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6
patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 88 patients will be accrued for this study.
We found this trial at
1
site
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
Click here to add this to my saved trials
